대한간학회

일시: 2026.8.29 (토)
장소: 유한양행 윌로우하우스, 3F 뉴스퀘어홀
※ Session 3, 4는 한–일 동시통역이 제공됩니다.

08:55-09:00	개회사	전대원(대한간학회 지방간연구회 회장)
09:00-09:05	환영사	임영석(대한간학회 이사장)
Session 1.	Redefining MASLD: Alcohol, Cardiometabolic Risk, and Disease Stratification	좌장: 장병국(계명의대), 조용균(성균관의대)
09:05-09:25	Background and Emerging Issues in MASLD and cardiovascular-kidney-metabolic syndrome era	김태형(고려의대)
09:25-09:45	Alcohol Exposure in MASLD: Limits of Current Thresholds and Emerging Approaches	김정희(한림의대)
09:45-10:05	Cardiometabolic Risk in MASLD: Beyond Current Criteria Toward Prognostic Refinement	유성환(연세의대)
10:05-10:25	Beyond Cardiometabolic Risk in MASLD: Kidney Disease and Prognostic Implications	조영윤(중앙의대)
10:25-10:40	차담과 휴식
Session 2.	Pathophysiology of MASLD: From Mechanisms to Therapeutic Targets	좌장: 임영석(울산의대), 손주현(을지의대)
10:40-11:00	Genetic Susceptibility in MASLD: From PNPLA3 to Polygenic Risk	안지현(한양의대)
11:00-11:20	MetALD: Alcohol–Metabolic Interaction and Fibrosis Risk	서원효(이화약대)
11:20-11:40	Sarcopenia and Myokines: Systemic Drivers of MASLD Progression	박하나(건국의대)
11:40-12:00	Emerging Therapies for MASH: Beyond Resmetirom, Incretin, and FGF21	손원(성균관의대)
12:00-12:10	Panel Discussion
12:10-13:00	점심식사
Session 3.	Diagnostic Challenges and Risk Stratification in MASLD: Korea–Japan Perspectives (한-일 동시통역)	좌장: Yoshihiro Kamada (Osaka Univ), 박상훈(한림의대)
13:00-13:20	Biomarker Updates in MASLD: ELF, M2BPGi, Agile, Multi-omics, and AI-driven markers	Yuya Seko (Kyoto Prefectural Univ Med)
13:20-13:40	Screening and risk stratification of MASLD using transient elastography	김승업(연세의대)
13:40-14:00	2D Shear Wave Elastography-based Risk Stratification in Patients with MASLD	Satoshi Oeda (Saga Univ)
14:00-14:20	Clinical Insights from Biopsy-Based MASLD Cohorts in Korea and Japan	Hideki Fujii (Osaka Metropolitan Univ), 김순선(아주의대)
14:20-14:35	차담과 교류
Session 4	Practical Therapeutic Strategies in MASLD: From NIT-Guided Care to FGF21 and Incretin Therapies (한-일 동시통역)	좌장: Yoshio Sumida (International Univ Healthcare and Welfare), 이진우(인하의대)
14:35-14:55	Biopsy free NIT-Guided Treatment in MASLD: Determining Treatment Eligibility and Monitoring Response	Hirokazu Takahashi (Saga Univ)
14:55-15:15	FGF-21 Based Therapies in MASLD	장세영(경북의대)
15:15-15:35	Incretin-Based Therapies in MASLD: From GLP-1 Monotherapy to Multi-Agonists and Oral Agents	송정은(대구가톨릭의대)
15:35-15:55	SGLT2 inhibitor Based Therapies in MASLD	Dan Nakano (Kurume Univ)
15:55-16:15	Extrahepatic Outcomes of Incretin-Based Therapy in MASLD: Cardiovascular, Renal, and Metabolic Implications	김남훈(고려의대)
16:15-16:25	Panel Discussion
16:25-16:30	폐회사	윤아일린(대한간학회 지방간연구회 학술이사)

프로그램